[Treatment of lipid disorders in metabolic syndrome and type 2 diabetes. The place for fibrates].
Cybulska
Barbara
B
Instytut Zywności i Zywienia w Warszawie.
Kłosiewicz-Latoszek
L
L
D002995:Clofibric Acid / Q000627:therapeutic use*; D015897:Comorbidity; D003924:Diabetes Mellitus, Type 2 / Q000453:epidemiology* / Q000517:prevention & control; D050171:Dyslipidemias / Q000188:drug therapy* / Q000453:epidemiology*; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D015994:Incidence; D024821:Metabolic Syndrome / Q000453:epidemiology*; D009765:Obesity / Q000453:epidemiology / Q000517:prevention & control; D012307:Risk Factors; D040242:Risk Reduction Behavior
D000960:Hypolipidemic Agents; D002995:Clofibric Acid